Elsevier

Schizophrenia Research

Volume 113, Issues 2–3, September 2009, Pages 241-245
Schizophrenia Research

Poor outcome in chronic schizophrenia is associated with progressive loss of volume of the putamen

https://doi.org/10.1016/j.schres.2009.06.022Get rights and content

Abstract

Background

We have previously demonstrated that putaminal but not caudate volumes are associated with poor outcome in patients with chronic schizophrenia. Present longitudinal study was designed to investigate progressive differences in striatal volumes among chronic schizophrenia patients with different outcomes and healthy subjects.

Methods

Structural MRI scans were acquired at baseline and at follow-up four years later to evaluate volumetric changes in 26 poor-outcome schizophrenia patients, 23 good-outcome patients and 16 healthy subjects.

Results

Schizophrenia patients with different outcomes entered the study with similar volumes of the caudate nucleus and putamen. The rate of decline in volumes of the putamen was greater in patients with poor outcome than in the good-outcome group, so that their putaminal but not caudate volumes were significantly smaller at the time of follow-up. There were no differences in baseline and follow-up volumes of the putamen or in the rate of their progression among patients with schizophrenia and healthy comparison subjects. The caudate volumes were lower in schizophrenia patients than healthy subjects at baseline and follow-up, but showed no differential patterns of progression between the groups.

Conclusions

Volumes of the putamen may represent a longitudinal marker of treatment responsiveness and outcome in patients with chronic schizophrenia.

Introduction

Striatal abnormalities have been postulated and described in patients with schizophrenia, but, as attested by their recent review (Brandt and Bonelli, 2008), still remain inconclusive. While most of the first-episode schizophrenia studies reported normal volumes of the caudate nucleus, with only a third revealing volumetric reductions, findings in chronic schizophrenia patients were equally divided between its enlargement and no volumetric change. Fewer studies have assessed volumes of the putamen, but with near unanimity in reporting no changes in first-episode and putaminal enlargement in chronic schizophrenia patients. Given these indications of striatal expansion in chronic schizophrenia and the rich dopaminergic innervation of the basal ganglia, a relationship between the acute exposure to antipsychotic agents and striatal enlargement has been proposed, with differential effects from the typical and atypical antipsychotics (Shihabuddin et al., 1998). Whether typical vs. atypical affiliation of the agents plays a differential role in striatal changes in the long run has not been firmly established (Gur et al., 1998, Mamah et al., 2007, Navari and Dazzan, in press, Zhou et al., 2003). Several short-term longitudinal studies appear to support enlargement of the caudate nucleus in first-episode and chronic schizophrenia patients following exposure to typical neuroleptic agents (Chakos et al., 1994, Keshavan et al., 1994, Lieberman et al., 2001) and atypical agents (Massana et al., 2005, Okugawa et al., 2007), others revealed no progressive changes or even decline in its density with mostly atypical agents (Glenthoj et al., 2007, Heitmiller et al., 2004, Lang et al., 2001, McClure et al., 2008, Stip et al., 2008, Tauscher-Wisniewski et al., 2005) and a typical agent (Glenthoj et al., 2007), or its enlargement with the typical and shrinkage with the atypical neuroleptization (Chakos et al., 1995, Corson et al., 1999, Lang et al., 2004, Scheepers et al., 2001). Two longer-term studies that compared schizophrenia patients and healthy subjects found no progressive changes in the caudate nucleus or decline in its density (DeLisi et al., 1997, van Haren et al., 2007) in patients over at least 4 years of follow-up. Brief exposure of schizophrenia patients to quetiapine was reported to result in decreased putaminal density (Stip et al., 2008) and to risperidone — in putaminal enlargement (Glenthoj et al., 2007), but the single longitudinal assessment of the putamen with normal control group published to date uncovered no morphometric differences between schizophrenia patients and healthy comparison subjects (Wang et al., 2008).

We previously reported larger putamens in schizophrenia patients with good outcome than poor-outcome (Kraepelinian) patients and proposed that rather than being a consequence of prolonged neuroleptic exposure putaminal enlargement may be a marker of responsiveness to antipsychotic treatment with the corollary that its shrinkage may be associated with poor clinical outcome (Buchsbaum et al., 2003). In the present study, we followed a cohort of chronic good-outcome and poor-outcome schizophrenia patients over a four-year period in order to compare longitudinal progression of volumes of both the caudate nucleus and putamen.

Section snippets

Subjects

49 patients with schizophrenia (age at baseline scan 42.69 ± 12.29 years) and 16 healthy subjects (age at baseline 41.63 ± 12.23 years, t63 = 0.30, p = ns) were scanned twice approximately 4 years apart (4.10 ± 0.54 years for schizophrenia patients and 4.22 ± 0.52 years for healthy subjects, t63 = 0.76, p = ns; see full sample description in Mitelman et al., 2009). Schizophrenia patients and healthy subjects did not significantly differ in major demographic characteristics. Based on the predominant pattern of

Results

At baseline, there were no significant differences in absolute and relative volumes of the caudate nucleus or putamen among any of the compared groups (Table 1). There was a trend towards lower relative right caudate volumes in schizophrenia patients than in healthy subjects (F1, 62 = 3.87, p = 0.054).

Absolute and relative volumes of the caudate nucleus and putamen dwindled over the time to follow-up in both schizophrenia patients and healthy subjects, with no significant between-group differences

Discussion

Poor outcome in patients with chronic schizophrenia is associated with a more pronounced shrinkage of the putamen, which begins approximately two decades after the onset of the disease. We have recently demonstrated that in contrast to the deceleration of cortical gray matter decline with age in this cohort of patients with good outcome, cortical shrinkage in the poor-outcome group as they age remains unabated (Mitelman et al., 2009). Present results may suggest the dynamic spread of

Role of funding source

The funding agencies had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Contributors

Serge A. Mitelman participated in image processing, analyzed the data and wrote the manuscript. Emily L. Canfield and King-Wai Chu participated in image processing and analysis. Adam M. Brickman, Erin A. Hazlett and Lina Shihabuddin organized subject recruitment and scanning. Monte S. Buchsbaum designed the study and supervised image acquisition, processing and analysis.

Conflict of interest

The authors have no potential conflicts of interests to disclose.

Acknowledgements

This work was supported by NARSAD Young Investigator Award and NIMH MH 077146 grant to Serge A. Mitelman and by NIMH grants P50 MH 66392-01, MH 60023, and MH 56489 to Monte S. Buchsbaum.

References (30)

Cited by (50)

  • Enhanced baseline activity in the left ventromedial putamen predicts individual treatment response in drug-naive, first-episode schizophrenia: Results from two independent study samples

    2019, EBioMedicine
    Citation Excerpt :

    Our findings are consistent with a previous study reporting that the volume increase in putamen was associated with positive symptom improvement as measured by the RR of the PANSS Positive Symptoms subscale scores in drug-naive patients with schizophrenia after six weeks of antipsychotic treatment [7]. Our findings are also in line with a previous report that the volume increase in putamen was associated with a better outcome in schizophrenia [23]; in that study, the authors suggested that putamen enlargement may be an imaging marker of responsiveness to antipsychotic treatment. Similar findings were observed in another study as well [34].

  • Amygdala volume is reduced in early course schizophrenia

    2016, Psychiatry Research - Neuroimaging
  • Baseline putamen volume as a predictor of positive symptom reduction in patients at clinical high risk for psychosis: A preliminary study

    2015, Schizophrenia Research
    Citation Excerpt :

    Volume changes in the putamen are closely related to response to antipsychotic treatment (Taylor et al., 2005), and to symptoms and course of disease in schizophrenia (Brandt and Bonelli, 2008). Additionally, the size of the putamen has been linked to severity of positive symptoms (Gur et al., 1998), treatment response (Li et al., 2012; Taylor et al., 2005), and outcome (Mitelman et al., 2009). Abnormalities in putamen volume are already apparent in patients experiencing the first episode of psychosis (Glenthoj et al., 2007), and healthy relatives with high genetic risk for psychosis (Dougherty et al., 2012; Seidman et al., 1997), in whom the putamen volume is decreased when compared to controls.

View all citing articles on Scopus
View full text